Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Spectrum (SPPI) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Spectrum between March 17, 2022 to September 22, 2022 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholde ...

NEW YORK , Aug. 12, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. The lead plaintiff process was reopened by the Court. If you wish to serve as lead plaintiff, you must move the Court no later than September 24, ...

LOS ANGELES, Aug. 12, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Summit Therapeutics Inc. ("Summit" or "the Company") (NASDAQ: SMMT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between March 17, 2022 and September 22, 2022, inclusive (the "Class Per ...

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces the reopening of the Lead Plaintiff appointment process in a pending securities class action lawsuit on behalf of investors of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI). Investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of sha ...

Group 1 - The class action lawsuit against Spectrum Pharmaceuticals, Inc. involves allegations of securities fraud and unlawful business practices by the company and certain officers or directors [2][4] - Investors have until September 24, 2025, to request appointment as Lead Plaintiff if they purchased Spectrum securities during the Class Period [2] - The lawsuit specifically addresses misleading statements made by Spectrum regarding its Pinnacle Study, a clinical trial for the drug poziotinib aimed at treating lung cancer patients [4] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for class members [5] - The firm has been active in the field of securities class actions for over 85 years, continuing the legacy of its founder, Abraham L. Pomerantz [5]

PHILADELPHIA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (“Spectrum” or the “Company”) on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the “Class Period”). Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2 ...

PHILADELPHIA, Aug. 6, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period").Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025, s ...